Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.57 |
| ▸ | FEN1 | P39748 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291353 | 1.00 | ALOX5AP (0.57) | ALOX5APFEN1GPR119CHRNB2CHRNA4 | |
| SCHEMBL18291358 | 0.93 | ALOX5AP (0.50) | ALOX5APFEN1GPR119CHRNA3 | |
| SCHEMBL7372804 | 0.88 | CHRNB2 (0.60) | ALOX5APFEN1GPR119CHRNB2CHRNA4 | |
| SCHEMBL7371666 | 0.88 | CHRNB2 (0.60) | ALOX5APFEN1GPR119CHRNB2CHRNA4 | |
| SCHEMBL8437928 | 0.87 | CHRNB2 (0.61) | ALOX5APFEN1GPR119CHRNB2CHRNA4 | |
| SCHEMBL7418829 | 0.87 | ALOX5AP (0.53) | ALOX5APFEN1GPR119CHRNB2CHRNA4 | |
| SCHEMBL8435310 | 0.87 | CHRNB2 (0.61) | ALOX5APFEN1GPR119CHRNB2CHRNA4 | |
| SCHEMBL6195438 | 0.86 | ALOX5AP (0.52) | ALOX5APFEN1GPR119CHEK2HRH2 | |
| SCHEMBL6182367 | 0.86 | ALOX5AP (0.52) | ALOX5APFEN1GPR119CHEK2HRH2 | |
| SCHEMBL8436171 | 0.86 | ALOX5AP (0.48) | ALOX5APFEN1GPR119CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016194831-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | ALOX5AP 3913/4885FEN1 1799/4885GPR119 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.